Kymera Therapeutics Sends First IRF5 Degrader Into Humans, Testing a Long-Sought Autoimmune Target

Kymera Therapeutics has begun dosing participants in the first-ever clinical study of a drug designed to destroy interferon regulatory factor 5, a transcription factor that sits at the center of autoimmune inflammation yet has resisted conventional pharmacology for more than a decade. The KT-579 clinical trial, a Phase 1 study in healthy volunteers registered as NCT07412288, opened for enrollment in March 2026 at a single site operated by the contract research organization Celerion in Lincoln, Nebraska. If the molecule performs as preclinical data suggest, it could open a route to oral, targeted therapy for systemic lupus erythematosus and a cluster of related diseases that remain poorly controlled by existing treatments.

Why IRF5 Has Eluded Drug Developers

IRF5 belongs to the interferon regulatory factor family, a group of transcription factors that translate danger signals from Toll-like receptors 7, 8, and 9 into the production of type I interferons, tumor necrosis factor-α, interleukin-6, and interleukin-12/23. Genome-wide association studies have repeatedly linked gain-of-function IRF5 polymorphisms to susceptibility for lupus, Sjögren's syndrome, systemic sclerosis, and rheumatoid arthritis. The genetic evidence is among the most replicated in autoimmune disease research.

Yet no company has succeeded in bringing an IRF5-directed therapy to the clinic until now. The protein lacks a catalytic pocket that a classical small-molecule inhibitor could occupy, and its activation depends on a cascade of conformational changes — phosphorylation, dimerization, nuclear translocation — that are difficult to intercept with a single binding event. Bristol-Myers Squibb, Nimbus Therapeutics, and Ventus Therapeutics (now part of Roche) have all explored small-molecule inhibition of IRF5 or its immediate signaling partners, but none of those programs have advanced beyond preclinical stages in publicly available registries.

Kymera's solution bypasses inhibition entirely. KT-579 is a targeted protein degrader — a small molecule engineered to recruit an E3 ubiquitin ligase to IRF5, tagging the protein for disposal by the proteasome. Because the degrader acts catalytically, a single molecule of drug can cycle through multiple rounds of target elimination, theoretically achieving near-complete loss of IRF5 protein at exposures lower than those required for stoichiometric inhibition.

Design of the First-in-Human KT-579 Phase 1 Study

The trial is structured as a randomized, double-blind, placebo-controlled study with sequential single ascending dose (SAD) and multiple ascending dose (MAD) cohorts. Ninety-six participants between the ages of 18 and 55, with body mass indices of 18.0 to 32.0 kg/m², are expected to be randomized to receive either oral KT-579 or matched placebo. Participants must be free of clinically relevant medical history across cardiovascular, hepatic, renal, neurological, and immunological domains. Women who are pregnant, lactating, or planning pregnancy are excluded, and both male and female participants must adhere to specified contraception requirements.

Primary endpoints are the incidence of adverse events and serious adverse events, measured through Day 14 in the SAD portion and Day 38 in the MAD portion. Secondary endpoints map out a standard pharmacokinetic profile: maximum plasma concentration, time to maximum concentration, area under the concentration-time curve (from time zero to last measurable time point, to end of dosing interval, and extrapolated to infinity), terminal elimination half-life, and fraction of drug excreted unchanged in urine. The trial record also lists pharmacodynamic assessments, though the specific biomarkers — presumably measures of IRF5 protein levels or downstream cytokine suppression in circulating immune cells — are not detailed in the registry entry.

A data monitoring committee is overseeing the study. Primary completion is projected for December 2026, with overall completion on the same timeline.

Preclinical Rationale Supporting the Targeted Protein Degrader Clinical Trial

Kymera has disclosed preclinical results for KT-579 at scientific conferences and in investor communications. In the MRL/lpr mouse model of lupus, oral doses achieving greater than 85% IRF5 degradation produced reductions in proteinuria and 100% survival. In the NZB/W F1 spontaneous lupus model, daily dosing that maintained greater than 80% target degradation led to sustained decreases in proteinuria, circulating antinuclear antibodies, and total kidney lesion burden. In rheumatoid arthritis models, KT-579 blocked proinflammatory cytokines and reduced joint swelling. The company has stated that no adverse effects were observed at concentrations up to 200-fold above projected human efficacious levels, and that selectivity profiling across the detectable proteome showed no degradation of other IRF family members, including IRF3, IRF4, and IRF7.

These data provide the pharmacological logic for advancing first-in-human KT-579 into clinical testing, but translating transcription-factor degradation from inbred mouse strains to human immune biology carries uncertainties that only clinical pharmacodynamic data can resolve.

A Crowded Pathway, an Empty Target

KT-579 enters a lupus pipeline that has grown dense with molecules acting on the same broad signaling axis. Novartis has afimetoran, a TLR7/TLR8 inhibitor, in Phase 2. Merck KGaA's enpatoran targets the same receptors. Bristol-Myers Squibb's deucravacitinib, a TYK2 inhibitor already approved for psoriasis, is in Phase 3 for lupus — and TYK2 sits directly downstream of the type I interferon receptor that IRF5 helps activate. Biogen's dazukibart and BMS's litifilimab both deplete plasmacytoid dendritic cells via BDCA2, cutting off the cellular source of interferon production. AstraZeneca's anifrolumab, which blocks the type I interferon receptor itself, has been on the market since 2021.

What distinguishes KT-579 within this crowded interferon-pathway space is the level at which it intervenes. IRF5 integrates signals from multiple TLRs and drives expression of several cytokine families simultaneously. Degrading the protein could, in principle, suppress a broader downstream program than blocking any single receptor or kinase. Whether that breadth translates into greater efficacy, greater toxicity, or both is unknown.

Outside the interferon axis, the lupus landscape includes CD19-directed CAR-T therapies from Kyverna, Cabaletta Bio, and Novartis that have produced drug-free remissions in refractory patients; telitacicept, a dual BAFF/APRIL inhibitor approved in China and in global Phase 3 trials; dapirolizumab pegol, UCB and Biogen's anti-CD40L Fab' fragment in Phase 3; and cenerimod, an oral S1P1 receptor modulator from Idorsia in Phase 3. Cereblon-based degraders such as BMS's iberdomide, which eliminates the transcription factors Aiolos and Ikaros rather than IRF5, are in Phase 2 for lupus and represent the closest modality-level comparison.

Within IRF5 targeted protein degradation specifically, KT-579 has no registered clinical competitors. Ionis Pharmaceuticals has pursued an antisense oligonucleotide approach to reduce IRF5 mRNA, and Monte Rosa Therapeutics and Nurix Therapeutics have disclosed discovery-stage molecular-glue or degrader programs against the target, but none have entered human testing.

What This Trial Will and Will Not Answer

The study is designed to establish human tolerability and characterize drug exposure, not to test therapeutic hypotheses. No patients with lupus or any other autoimmune condition are enrolled. The pharmacodynamic readouts, once disclosed, will be the data to watch: they will indicate whether oral dosing in humans can achieve the degree of IRF5 protein reduction that drove efficacy in mouse models. If KT-579 demonstrates measurable, dose-dependent IRF5 degradation in circulating immune cells at tolerable exposures, Kymera would have a basis for advancing into patient studies — likely in lupus, given the genetic and mechanistic rationale, and potentially in Sjögren's syndrome, where no targeted therapy has yet received FDA approval.

Kymera also has a second degrader, KT-474, targeting IRAK4 — a kinase that operates in the same TLR-MyD88 signaling cascade, upstream of IRF5 — in Phase 2 for hidradenitis suppurativa and atopic dermatitis. The company will eventually need to articulate how two oral degraders acting on the same pathway but at different nodes are positioned relative to each other across indications.

For now, the KT-579 Phase 1 trial represents the first clinical test of whether a transcription factor long considered undruggable can be eliminated from human cells by a pill. The answer, expected by the end of 2026, will shape not only Kymera's pipeline but also the broader question of how far targeted protein degradation can reach into immunology.

---

Spot something wrong? Report an issue with this article